GLP-1 Microdosing Guide: How to Run a Sub-Standard Protocol

What Is GLP-1 Microdosing? A Quick Orientation

A microdose is any GLP-1 schedule that intentionally runs below the labeled trajectory. In practice that splits into two camps. Sub-start dosing means using less drug per week than the labeled starting dose: under 0.25mg for semaglutide, under 2.5mg for tirzepatide, under 2mg for retatrutide. Extended-hold means using the standard starting dose but holding there for eight to twelve weeks instead of escalating at week four.

Neither approach has FDA approval. There is no agency-blessed microdosing protocol for any GLP-1. Every schedule below covers what some practitioners and patients actually do off-label, with a licensed prescriber. The full conceptual treatment, the evidence base, and the risk framing live in our what microdosing GLP-1 means explainer.

Sub-start versus extended-hold at a glance

Why Half-Life Determines Your GLP-1 Microdosing Protocol

Half-life is the practical reason microdosing feels different across compounds. The longer the half-life, the smoother the peak-to-trough plasma curve at any dose. That smoothness is exactly what most microdosers want: less of the early-week nausea spike that drives people off-label in the first place.

Semaglutide sits at approximately 7 days, which is why it shows up most often in microdosing discussions. Retatrutide is approximately 6 days (Urva et al., 2022, The Lancet). Tirzepatide is the shortest at approximately 5 days. At any given dose level, tirzepatide reaches steady state in about 4 weeks and semaglutide in 4 to 5 weeks, per their labels; retatrutide has no label, so its roughly 4 to 5 weeks is an estimate from its half-life. That window is the floor for any "did this dose work" judgment. Calling a dose insufficient at week three is reading the accumulation curve, not the drug effect.

You can visualize any sub-standard dose's accumulation curve in the free GLP-1 dose plotter. For the full pharmacokinetic table broken out by compound, see the GLP-1 microdosing reference chart.

Plasma concentration curves over 14 days. Semaglutide (about 7 days) declines slowest; retatrutide (about 6 days) sits in the middle; tirzepatide (about 5 days) falls fastest.

Who Should Consider Microdosing GLP-1?

Three scenarios cover most of the clinical use. None of them are a green light. Each one still belongs in a prescriber's office, not a forum thread.

GI intolerance at standard doses

The Kouyoumdjian et al. 2025 letter in Diabetes Care identifies gastrointestinal adverse effects as the primary clinical rationale for reaching for a microdose. Dose-proportional nausea, diarrhea, constipation, and vomiting are the most common reasons patients abandon GLP-1 therapy at any dose. Lower peak plasma concentrations may reduce that burden. Individual response varies.

Maintenance after hitting a weight target

Readers who have reached a goal weight and want the lowest effective dose for maintenance often gravitate toward extended-hold or further dose reduction. The trial data does not extend below labeled doses, so this territory is empirical.

Cost-reduction imperative

Compounded formulations at lower doses are a lower-cost access route for some users. The clinical oversight requirement does not change, and compounded products carry their own quality-control questions worth discussing with a prescriber before starting.

How to Microdose Semaglutide (Ozempic, Wegovy, Compounded)

Semaglutide is the most popular target for microdosing for two reasons: the half-life is the longest of the three (about 7 days, so trough levels stay high) and brand-name pens come pre-filled at the 0.25mg starting dose, which makes extended-hold the easiest of any GLP-1 to run.

Approach A: extended-hold at 0.25mg

No compounding required. Works with Ozempic, Wegovy, or any branded semaglutide pen.

1. Begin at the standard 0.25mg weekly dose (the STEP 1 starting dose).
2. Hold at 0.25mg for 8 to 12 weeks rather than escalating at the labeled four-week mark.
3. Track GI tolerance, appetite, and weight trend weekly.
4. Escalate only when GI tolerance is established AND appetite suppression is insufficient. Prescriber concurrence required.

Decision rule: if nausea is still pronounced at week four on 0.25mg, hold instead of escalating. If it resolves by week six to eight, escalation under prescriber guidance becomes a reasonable next conversation. STEP 1 reported approximately 14.9% average body weight loss at 68 weeks on the full 2.4mg dose; extended-hold at 0.25mg does not target that result.

Approach B: sub-start with compounded semaglutide

Requires a compounded semaglutide product from a 503A compounding pharmacy at a sub-0.25mg concentration. Some practitioners describe starting in the very-low-dose range; no peer-reviewed source defines a specific sub-start threshold. The 0.05-0.1mg figure seen in community discussions is not a clinically validated number, only a description of what some patients run.

• Titrate slowly: hold at each dose level for at least four weeks before considering an escalation.
• Model the curve in the plotter before changing doses. Trough levels at sub-start doses can swing surprisingly with small adjustments.
• Sub-start protocols are fully prescriber-designed. There is no published reference schedule.

For the deep-dive on semaglutide-specific microdose schedules, see the semaglutide microdosing guide.

How to Microdose Tirzepatide (Mounjaro, Zepbound, Compounded)

Tirzepatide is a special case in any GLP-1 microdosing guide. Its FDA-labeled starting dose, 2.5mg weekly, is already the floor of the approved range. Extended-hold at 2.5mg is therefore the most common "microdosing" approach for brand-name users, even though pharmacologically 2.5mg is the label, not a sub-label dose. Sub-2.5mg requires compounding.

Approach A: extended-hold at 2.5mg

No compounding required. Works with Mounjaro or Zepbound pens.

1. Begin at the standard 2.5mg Mounjaro or Zepbound starting dose.
2. Hold at 2.5mg for 8 to 12 weeks rather than escalating to 5mg at week four.
3. Evaluate at week 8: is appetite control adequate? Is GI tolerance established?
4. If both yes, discuss escalation timing with your prescriber. SURMOUNT-1 reached approximately 20.9% mean body weight loss at 72 weeks on 15mg, so escalation is on the table if results warrant it.
5. If appetite control is adequate at 2.5mg, extended-hold can continue indefinitely under prescriber guidance.

One framing point worth keeping straight: 2.5mg is not a pharmacological microdose, it is the labeled floor. Extended-hold is a clinical pacing strategy, not sub-therapeutic dosing. The GLP-1 microdosing reference chart covers that distinction in detail.

Approach B: sub-2.5mg with compounded tirzepatide

Genuinely sub-label dosing requires a compounded product from a 503A pharmacy. A common starting point cited in clinical descriptions is 1mg weekly for four weeks, then re-assess. No randomized controlled trial data exists for tirzepatide below 2.5mg, so the dose-response relationship at sub-start levels is empirical rather than evidence-based. GLP-1 and GIP receptor engagement still occurs at lower doses; the clinical outcome at those doses is not characterized in peer-reviewed literature.

For dose-level protocols specific to tirzepatide, see the tirzepatide microdosing guide.

Can You Microdose Retatrutide? Not Lawfully

Retatrutide is investigational. Eli Lilly's triple-agonist (GLP-1, GIP, glucagon) has no FDA approval as of 2026, and the FDA states that retatrutide "cannot be used in compounding under federal law." The FDA also describes products falsely labeled "for research purposes" or "not for human consumption" as illegally sold unapproved drugs. In the US, the routes available today are a clinical trial or Lilly's expanded access program (ClinicalTrials.gov NCT07629401), which a doctor must request, for adults with a BMI of 35 or more whose obesity has not responded to the highest available dose of current weight-loss treatment, who have two or more serious obesity-related complications, and who cannot join a trial. Lilly provides the product at no cost, but the doctor must apply to the FDA as sponsor of a patient-specific investigational new drug (IND) application and obtain institutional review board (IRB) approval, and Lilly does not ship directly to patients (per Lilly Medical). Neither route provides retatrutide for a self-designed schedule, so there is no lawful microdosing route.

The only dosing evidence comes from trials. The Phase 2 obesity trial (Jastreboff et al., 2023, NEJM) ran fixed weekly arms of 1mg, 4mg, 8mg and 12mg; the higher arms started at 2mg (or 4mg in some groups) and stepped up every four weeks, reaching approximately 24.2% body weight loss at 48 weeks on the 12mg arm. Doses under 2mg were tested only as fixed weekly arms (0.5mg to 1.5mg, in a Phase 1b study and a Phase 2 type 2 diabetes trial, plus a 1mg arm in the Phase 2 obesity trial) or as single doses in Phase 1; no trial tested split or microdosing schedules.

If you want access to retatrutide, enrollment in a retatrutide clinical trial is the main lawful route, but most retatrutide Phase 3 trials are no longer enrolling; check ClinicalTrials.gov for open studies. The expanded access program is limited to a small group of patients whose doctor requests it. For the legal detail, see why compounded retatrutide is prohibited; for the pharmacokinetics of split schedules, see the retatrutide microdosing deep-dive and the retatrutide side effects guide.

Titration Decision Framework (Semaglutide and Tirzepatide)

The same three-state decision applies to every semaglutide or tirzepatide microdosing schedule: hold, escalate, or reduce. The rules below are practitioner-style heuristics built on the trial titration intervals (4 weeks) and the steady-state window (about 4 weeks for tirzepatide, 4 to 5 weeks for semaglutide, at any dose).

Hold-Escalate-Reduce decision tree applied to semaglutide and tirzepatide microdose schedules.

Hold at the current dose if

• GI symptoms (nausea, diarrhea, vomiting, constipation) are still present at the current dose
• You have not yet reached steady state at this dose level (about 4 weeks for tirzepatide, 4 to 5 for semaglutide)
• Appetite suppression is sufficient for your goals at the current dose

Escalate if

• GI tolerance is established (no significant symptoms past week 4-6)
• Steady state has been reached at the current dose (about 4 weeks for tirzepatide, 4 to 5 for semaglutide)
• Appetite suppression is insufficient and weight trend has plateaued
• Prescriber concurs

Reduce if

• GI side effects are severe or persistent past 8 weeks at the current dose
• Appetite suppression is more aggressive than intended, with loss of interest in food creating concern
• Prescriber recommends reduction

Using the GLP-1 plotter for protocol modeling

Before any escalation or reduction, run the proposed schedule in the free pharmacokinetic calculator. Enter your compound, current dose, and weekly frequency. The plotter outputs your accumulation curve and shows when steady state is reached at any new dose level. That preview helps you see how trough levels will move before the change happens in your body.

Common Protocol Mistakes to Avoid

A short watchlist of the things that go wrong most often in a self-managed microdose schedule:

1. Escalating before steady state. Calling 0.25mg semaglutide insufficient at week three reads normal accumulation as a failed response. Wait the full 4-5 weeks before judgment.
2. Click-counting on brand-name pens. Brand pens are not designed for precision below labeled doses. Counting clicks to approximate a sub-start dose introduces measurement error that compounds week over week.
3. Self-managing without a prescriber. Off-label dosing without medical monitoring is a category of risk the calculator can not model.
4. Treating lower dose as zero risk. GI side effects, pancreatitis signals, and the other GLP-1 effects can occur at any dose. Lower dose reduces the rate, not the existence.
5. Conflating cost reduction with clinical strategy. Microdosing for budget reasons is valid; it still requires the same prescriber oversight as any other dosing decision.